Liquid Biopsy Based Circulating Biomarkers in Metastatic Prostate Cancer

Eshwari Dathathri, Khrystany T. Isebia, Fikri Abali, Martijn P. Lolkema, John W.M. Martens, Leon W.M.M. Terstappen*, Ruchi Bansal

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

4 Citations (Scopus)
4 Downloads (Pure)


Prostate cancer is the most dominant male malignancy worldwide. The clinical presentation of prostate cancer ranges from localized indolent to rapidly progressing lethal metastatic disease. Despite a decline in death rate over the past years, with the advent of early diagnosis and new treatment options, challenges remain towards the management of metastatic prostate cancer, particularly metastatic castration sensitive prostate cancer (mCSPC) and castration resistant prostate cancer (mCRPC). Current treatments involve a combination of chemotherapy with androgen deprivation therapy and/or androgen receptor signalling inhibitors. However, treatment outcomes are heterogeneous due to significant tumor heterogeneity indicating a need for better prognostic biomarkers to identify patients with poor outcomes. Liquid biopsy has opened a plethora of opportunities from early diagnosis to (personalized) therapeutic disease interventions. In this review, we first provide recent insights about (metastatic) prostate cancer and its current treatment landscape. We highlight recent studies involving various circulating biomarkers such as circulating tumor cells, genetic markers, circulating nucleic acids, extracellular vesicles, tumor-educated platelets, and the secretome from (circulating) tumor cells and tumor microenvironment in metastatic prostate cancer. The comprehensive array of biomarkers can provide a powerful approach to understanding the spectrum of prostate cancer disease and guide in developing improved and personalized treatments for patients.

Original languageEnglish
Article number863472
JournalFrontiers in oncology
Publication statusPublished - 20 May 2022


  • circulating biomarkers
  • circulating tumor cells (CTC)
  • extracellular vesicles (EVs)
  • Metastatic prostate cancer
  • prognostic biomarkers
  • secretory factors
  • UT-Gold-D


Dive into the research topics of 'Liquid Biopsy Based Circulating Biomarkers in Metastatic Prostate Cancer'. Together they form a unique fingerprint.

Cite this